Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 16/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | PDCD1LG2 | Q9BQ51 | 8/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15254386 | 0.67 | CYP1A2 (0.48) | KDM4ETSHRCRBN | |
| SCHEMBL15254389 | 0.67 | CYP1A2 (0.48) | KDM4ETSHRCRBN | |
| SCHEMBL30073110 | 0.67 | KDM4E (0.72) | KDM4EALOX15TSHRSIRT1 | |
| SCHEMBL30073106 | 0.67 | KDM4E (0.72) | KDM4EALOX15TSHRSIRT1 | |
| SCHEMBL19028093 | 0.67 | HTR1A (0.58) | KDM4EALOX15TSHRSIRT1DPP4 | |
| SCHEMBL1776113 | 0.66 | DDB1 (0.44) | CD274PDCD1KDM4ECRBNPDCD1LG2 | |
| SCHEMBL22201152 | 0.65 | ACHE (0.52) | TSHRCRBN | |
| SCHEMBL22190395 | 0.65 | ACHE (0.52) | TSHRCRBN | |
| SCHEMBL32686179 | 0.65 | PLA2G1B (0.43) | KDM4EALOX15TSHRSIRT1DPP4 | |
| SCHEMBL19852202 | 0.65 | KDM4E (0.55) | KDM4EALOX15TSHRSIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | HAVCR2, HMBS, VHL | CD274 75/4885PDCD1 62/4885KDM4E 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.